In Vitro Imaging and Quantification of the Drug Targeting Efficiency of Fluorescently Labeled GnRH Analogues
- PMID: 28362408
- PMCID: PMC5409304
- DOI: 10.3791/55529
In Vitro Imaging and Quantification of the Drug Targeting Efficiency of Fluorescently Labeled GnRH Analogues
Abstract
GnRH analogues are effective targeting moieties and able to deliver anticancer agents selectively into malignant tumor cells which highly express GnRH receptors. However, the quantitative analysis of GnRH analogues' cellular uptake and the investigated cell types in GnRH-based drug delivery systems are currently limited. Previously introduced, selectively labeled fluorescent GnRH I, -II and -III derivatives provide great detectability, and they have suitable chemical properties for reproducible and robust experiments. We also found that the appropriate up-to-date methods with these labeled GnRH analogues could offer novel information about the GnRH-based drug delivery systems. This manuscript introduces some simple and fast experiments regarding the cellular uptake of [D-Lys6(FITC)]-GnRH-I, [D-Lys6(FITC)]-GnRH-II and [Lys8(FITC)]-GnRH-III on the EBC-1 (lung), the BxPC-3 (pancreas) and on the Detroit-562- (pharynx) malignant tumor cells. In parallel with these GnRH-FITC conjugates, the cell surface level of GnRH-I receptors was also examined on these cell lines before and after the GnRH treatment by confocal laser scanning microscopy. The cellular uptake of GnRH-FITC conjugates was quantified by fluorescence-activated cell sorting. In these experiments minor differences among GnRH analogues and major differences among cell types was observed. The significant differences among cell lines are correlated with their distinct level of cell surface GnRH-I receptors. The introduced experiments contain practical methods to visualize, quantify and compare the uptake efficiency of GnRH-FITC conjugates in a time- and concentration-dependent manner on various adherent cell cultures. These results could predict the drug targeting efficiency of GnRH conjugates on the given cell culture, and offer a good basis for further experiments in the examination of GnRH-based drug delivery systems.
Similar articles
-
Synthesis, characterization and systematic comparison of FITC-labelled GnRH-I, -II and -III analogues on various tumour cells.J Pept Sci. 2016 Aug;22(8):552-60. doi: 10.1002/psc.2904. J Pept Sci. 2016. PMID: 27443981
-
Development of novel 68Ga- and 18F-labeled GnRH-I analogues with high GnRHR-targeting efficiency.Bioconjug Chem. 2008 Jun;19(6):1256-68. doi: 10.1021/bc800058k. Epub 2008 May 30. Bioconjug Chem. 2008. PMID: 18510351
-
Novel Crizotinib-GnRH Conjugates Revealed the Significance of Lysosomal Trapping in GnRH-Based Drug Delivery Systems.Int J Mol Sci. 2019 Nov 8;20(22):5590. doi: 10.3390/ijms20225590. Int J Mol Sci. 2019. PMID: 31717403 Free PMC article.
-
AEZS-108 : a targeted cytotoxic analog of LHRH for the treatment of cancers positive for LHRH receptors.Expert Opin Investig Drugs. 2012 Jun;21(6):891-9. doi: 10.1517/13543784.2012.685128. Expert Opin Investig Drugs. 2012. PMID: 22577891 Review.
-
New drug delivery strategies targeting the GnRH receptor in breast and other cancers.Endocr Relat Cancer. 2021 Sep 8;28(11):R251-R269. doi: 10.1530/ERC-20-0442. Endocr Relat Cancer. 2021. PMID: 34236041 Review.
References
-
- Majumdar S, Siahaan TJ. Peptide-mediated targeted drug delivery. Med Res Rev. 2012;32(3):637–658. - PubMed
-
- Ramakrishnappa N, Rajamahendran R, Lin YM, Leung PCK. GnRH in non-hypothalamic reproductive tissues. Anim Reprod Sci. 2005;88(1-2):95–113. - PubMed
-
- Schally AV, et al. Hypothalamic hormones and cancer. Front Neuroendocrinol. 2001;22(4):248–291. - PubMed
-
- Limonta P, et al. GnRH receptors in cancer: From cell biology to novel targeted therapeutic strategies. Endocr Rev. 2012;33(5):784–811. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources